Erschienen in:
28.11.2019 | PRECLINICAL STUDIES
Matteucinol, isolated from Miconia chamissois, induces apoptosis in human glioblastoma lines via the intrinsic pathway and inhibits angiogenesis and tumor growth in vivo
verfasst von:
Ana Gabriela Silva, Viviane Aline O. Silva, Renato J. S. Oliveira, Allisson Rodrigues de Rezende, Rafael César Russo Chagas, Lúcia Pinheiro Santos Pimenta, Wanderson Romão, Hélio Batista Santos, Ralph Gruppi Thomé, Rui Manuel Reis, Rosy Iara Maciel de Azambuja Ribeiro
Erschienen in:
Investigational New Drugs
|
Ausgabe 4/2020
Einloggen, um Zugang zu erhalten
Summary
Gliomas account for nearly 70% of the central nervous system tumors and present a median survival of approximately 12–17 months. Studies have shown that administration of novel natural antineoplastic agents is been highly effective for treating gliomas. This study was conducted to investigate the antitumor potential (in vitro and in vivo) of Miconia chamissois Naudin for treating glioblastomas. We investigated the cytotoxicity of the chloroform partition and its sub-fraction in glioblastoma cell lines (GAMG and U251MG) and one normal cell line of astrocytes. The fraction showed cytotoxicity and was selective for tumor cells. Characterization of this fraction revealed a single compound, Matteucinol, which was first identified in the species M. chamissois. Matteucinol promoted cell death via intrinsic apoptosis in the adult glioblastoma lines. In addition, Matteucinol significantly reduced the migration, invasion, and clonogenicity of the tumor cells. Notably, it also reduced tumor growth and angiogenesis in vivo. Moreover, this agent showed synergistic effects with temozolomide, a chemotherapeutic agent commonly used in clinical practice. Our study demonstrates that Matteucinol from M chamissois is a promising compound for the treatment of glioblastomas and may be used along with the existing chemotherapeutic agents for more effective treatment.